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Available online 1 November 2016A potent anti-vascular endothelial growth factor (VEGF) biologic and a compatible delivery systemwere co-eval-
uated for protection againstwet age-relatedmacular degeneration (AMD) over a 6month period following a sin-
gle intravitreal (IVT) injection. The anti-VEGF molecule is dimeric, containing two different anti-VEGF domain
antibodies (dAb) attached to a human IgG1 Fc region: a dual dAb. The delivery system is based onmicroparticles
of PolyActive™ hydrogel co-polymer. The molecule was evaluated both in vitro for potency against VEGF and in
ocular VEGF-driven efﬁcacymodels in vivo. The dual dAb is highly potent, showing a lower IC50 than aﬂibercept in
VEGF receptor binding assays (RBAs) and retaining activity upon release from microparticles over 12 months in
vitro. Microparticles released functional dual dAb in rabbit and primate eyes over 6 months at sufﬁcient levels to
protect Cynomolgus against laser-induced grade IV choroidal neovascularisation (CNV). This demonstrates proof
of concept for delivery of an anti-VEGFmolecule within a sustained-release system, showing protection in a pre-
clinical primate model of wet AMD over 6 months. Polymer breakdown and movement of microparticles in the
eye may limit development of particle-based approaches for sustained release after IVT injection.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Neovascular AMD is the most common cause of legal blindness in
industrialised countries [1,2]. Pharmacotherapy by IVT administra-
tion of VEGF inhibitors has greatly improved patient outcomes [1,2,Centre, Gunnels Wood Road,
le).
. This is an open access article under3], but the need for continuous therapy requiring frequent clinical
visits for an increasing elderly population has become an issue [3].
Researchers and clinicians have been trying to extend IVT adminis-
tration beyond monthly (ranibizumab) or bimonthly (aﬂibercept)
labels [1]. The generation and validation of a controlled release sys-
tem for wet AMD, with efﬁcacy equivalent to standard of care
(SoC), but enabling IVT administration once every six months is a
signiﬁcant goal [4]. Ocular implants for release of small molecule
anti-inﬂammatory agents are already approved [5,6], and somethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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trials for extended delivery of VEGF inhibitors [7,8]. The Forsight Vi-
sion 4/Genentech evaluation of a reﬁllable device which is aiming to
be topped up with ranibizumab every four months using a special
loading needle is recruiting for a Phase II study [7]. Neurotech have
performed both Phase I and II clinical trials with their intravitreally
implanted encapsidated cell therapy device, (ECT), containing a cell
line secreting a highly potent VEGF inhibitor, although the procedure
appears well-tolerated, the Phase II trial was recently halted due to
lack of reproducible long term efﬁcacy [8]. However, no ocular con-
trolled release system, administered by a simple IVT injection via a
30 g needle, enabling long-term biologic exposure has progressed
beyond pre-clinical studies, [9]. A recent review emphasizes signiﬁ-
cant hurdles for integrating biologics within delivery matrices with-
out disrupting their molecular integrity and activity. Controlling
release rate to achieve therapeutic levels of biologics for more than
a few months has been challenging [9].
In this paper, we address many of these challenges and describe a
slow-release system with a potent anti-VEGF biologic [10]. TheFig. 1. (A) Schematic of anti-VEGF biologics: dual dAb, 109 kD, VEGF dAb-Fc, (top half, dual dA
formulations: (B) Particle size analysis, 72F, (Table 1, Fig. S1A), (C) light microscopy analysis
magniﬁcation, 72F (yellow squares are displayed at 3× magniﬁcation in Fig. S1D).domain antibody based, dual dAb molecule [10,11] and a compatible
delivery system were co-evaluated with the aim to generate a prod-
uct for wet AMD, delivering 6 month protection after a single IVT in-
jection. The delivery system is based on PolyActive™, polyethylene
glycol–polybutylphthalate (PEG-PBT) hydrogel co-polymer micro-
particles [12,13]. The system and released molecule were evaluated
in vitro for functionality and potency and in vivo in VEGF-driven oc-
ular efﬁcacy models.
2. Materials and methods
2.1. Study design
Objective was to show VEGF dual dAb (Fig. 1A), could load
PolyActive microparticles in sufﬁcient amounts to allow release of func-
tionally active molecule in vitro and in vitreous over 6 months at levels
capable of protecting in a Cynomologus model of wet AMD. Achieve-
ment was demonstrated by physical and functional molecular assays
in vitro, with in vivo experiments in rabbit and Cynomolgus. Assaysb), 79 kD, VEGF Fc-dAb, (bottom half, dual dAb), 79 kD. Characterisation of microparticle
at high magniﬁcation, 1000× (D) Scanning Electron Microscopy (SEM) analysis at low
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sigmoidal dose response using 4PL curveswere used to generate EC50 or
IC50 values and for PK analyses, noncompartmental PK withWinNonlin
™ (WNL) v6.3 and tissue values were calculated assuming an extract
density of 1 g/ml, i.e. tissue conc (ng/g) = extract conc (ng/
ml) × extract weight / tissue weight (g). Animal studies were non-
blinded, randomised pre-screened to exclude ocular abnormalities,
pre-existing ADA responses or elevated baselines to immunoassays for
ADA analyses positive cut-off points and outliers were determined
based upon baseline measures (background+ 1.645 × SD or mean sig-
nal for all tested samples + 3.09 × STDEV and ADA positives were ex-
cluded from PK and efﬁcacy analyses. Group sample size for rabbit and
Cynomolgus PK studies were chosen using variance in past experi-
ments, for the laser CNV study aminimum sample size n=6was deter-
mined from previous analyses, (Covance database). Animal welfare
(NIH) and reporting (ARRIVE, EQUATOR) guidelines were followed.
2.2. Generation and puriﬁcation of domain antibody-based proteins
This was performed using phage-display isolation and standard tech-
nologies, for details see Supplementary data: materials and methods.
2.3. Particle sizing, light and scanning electron microscopy and protein re-
lease measurements
These were performed using standard methodology, for details see
Supplementary data: materials and methods.
2.4. Functional, molecular integrity and receptor binding assays
These assays utilisedmesoscale discovery platform (MSD) technolo-
gy performed according to manufacturer's recommendations (MSD),
for details see Supplementary data: materials and methods.
2.5. Cynomolgus PK and efﬁcacy studies and pharmacokinetic modelling
Long term PK and efﬁcacy studies are shown schematically in Figs.
3A and 4A, respectively and the extension of the efﬁcacy study in Fig.
S6A. Empty microparticles were prepared from the same polymer as
72F, as a negative control: Group 1, (Fig. S1A). IVT injections were per-
formed on anesthetized animals and are described in detail in Supple-
mentary data: materials & methods, post-injection management
included infection, pain and inﬂammation control. For details of the for-
mulation administration, laser CNV, FA and extended PK studies and the
pharmacokinetic modelling using WinNon lin™ and MATLAB see Sup-
plementary data: materials & methods.
2.6. Statistics
For analysis of CNV lesion data, Fisher's exact tests in the R statistical
environment compared the treatment groups based on a contingency
table at each time point, [14,15], together with Poisson regression anal-
ysis, [16], to model count data at each time point with Dunnett's adjust-
ed P-values in SAS using PROC GENMOD with JMP software used for
data visualisation. Animals I00079, I00084, and I00085 were excluded
from all analyses due to impact of ADA, (Table S6). Modelling simula-
tions used a 2-compartment model (vitreous and serum) relying on
compartment volumes and elimination rates determined from naked
dual dAb ocular and systemic PK studies. For loadedmicroparticle stud-
ies, themodel was extended to include a drug depot parameter: ‘releas-
ing into the vitreous’- release rate being deﬁned by in vitro release data
and adjusted with in vivo release data. SoC anti-VEGFs were simulated
using a 1-compartment model and clearance rates from published
data, details with codes and algorithms are shown in Supplementary
data: materials and methods.2.7. Study approval
All animal studies were reviewed and approved by the appropriate
ethical review boards for animal experimentation under the existing li-
cences. Rabbit studies, (GSK, UK) and non-human primate studies,
(Covance, USA).
3. Results
3.1. Domain antibody molecules to VEGF
Differentmolecular formats are depicted in Fig. 1A, dual dAb; dAb-Fc
and Fc-dAb: dual dAb, without C-terminal Vκ dAbs or N-terminal VH
dAbs, respectively. All molecules are homodimers linked by cysteine
bridges, based upon human immunoglobulin G1 subclass Fc domain
(IgG1Fc).
3.2. Generation and analysis of dual dAb-loaded PolyActive microparticles
Liquid concentrated dual dAb was incorporated into six PolyActive
microparticle formulations with mean particle diameters of 62–66 μm,
encapsulation-efﬁciencies of ≥72% and protein loading of ≥15.3%, weight
by weight, (w/w) using the water-in-oil-in-water emulsion (w/o/w)
process, (Table 1, Fig. 1B, C, D, Fig. S1). The aimwas to test variant formu-
lations across three parameters: PEG length, PEG:PBT ratio and water/
polymer (w/p) ratio, for dual dAb-release rate. In vitro release proﬁles
show a small burst after 1 day (b20%), a potential loading dose suitable
for immediate VEGF blockade; a predicted release period of: 6 months
for formulations 72B and 72E, (‘fast’); 9–12 months for 72F, (‘intermedi-
ate’) and 12–18months for 72A, 72C and 72D, (‘slow’), (Fig. 2A, Fig. S2A).
In vitro release was monitored from all formulations for 6 months and
extended to 12months for 72F. Post-experiment dual dAbmass balances
(‘retained’ plus ‘released’) of 79–95% were conﬁrmed, with 84% release
of dual dAb from 72F achieved by month 12, (Table 1).
3.3. Functional activity of dual dAb released from microparticle in vitro
Functional activity of released dual dAb in VEGF binding immunoas-
says was retained at N90%, over 6 months in all formulations except for
72A and 72D (70–90%), (Fig. 2B). Some partial dual dAb cleavage oc-
curred at days 21–182, but after 6 months, molecular integrity was
N50% after release from formulations 72B, 72E and 72F. Dual dAb func-
tional activity was retained at N85% after 6–12months release from 72F
and protein integrity was ≥50% at 10 months (40% after 12 months).
Functional activity for released, (72B, 72E and 72F) dual dAb was
retained best in the VEGF R2 RBA, whereas 72D (‘slow’) activity de-
creasedwith time, (Fig. S2B, S2C and Table S1). Partial cleavage at linker
regions could be identiﬁed from the in vitro release samples, generating
N-terminal Vh dAb-Fc or C-terminal Vk Fc-dAbmolecule (Fig. 1A), both
of which maintain anti-VEGF activity, Fc-dAb with similar potency to
dual dAb and aﬂibercept. After 5–6 months, dual dAb released from
72B, 72E and 72F had IC50 values close to naked molecule and
aﬂibercept in the VEGF R2 RBA, (Fig. 2C).
3.4. Ocular PK from dual dAb-loaded microparticles in rabbit
Ocular pharmacokinetic (PK) experiments were performed with
both naked dual dAb (Fig. S3A) and dual dAb loaded microparticles in
rabbit, (Fig. S3B). Anti-drug antibody (ADA) responses were noted in
serum and ocular samples. Ocular half-life of naked dual dAb, in ADA
free animals, was 4.3 days, (Fig. S3A). An ocular PK study was undertak-
en in rabbit to compare the in vitro release rate of dual dAb to that in
vivo, after IVT injection of three formulations: 72A (fast), 72B (slow)
and 72F (intermediate). At 6 months, ADA-free rabbits dosed with 72F
maintained signiﬁcant vitreal levels of dual dAb (1 μg/ml) whereas
those dosed with 72B maintained about 10-fold lower levels. Rabbits
Table 1
Characterisation of dual dAb-loaded microparticle.
Formulation w/p
ratio
PSA
d(0.5) μm
PolyActive recovery
(mg/vial)
Protein loading
(mg/vial)
Protein
loading (%)
Protein
EE (%)
% release
6 mo (12 mo)
% residual
6 mo (12 mo)
% mass-balance
6 mo (12 mo)
72A (1000/70/30) 1.2 63 19.9 4.27 17.7 83 44.5 34.6 79.1
72B (1000/72.5/27.5) 1.2 66 30.6 5.54 15.3 72 94.0 0.0 94.0
72C (1500/70/30) 1.2 64 32.7 7.11 17.9 82 35.0 59.5 94.5
72D (1000/70/30) 1.35 62 17.7 4.23 19.3 81 54.4 31.0 85.4
72E (1000/72.5/27.5) 1.35 64 22.6 5.23 18.8 77 86.5 0.1 86.6
72F (1500/70/30) 1.35 64 27.2 7.70 22.1 90 66.1 (83.8) 25.4 (5.1) 91.5 (88.9)
PolyActive formulations are: (PEG length/PEG%age/PBT%age), w/p = water/polymer ratio, PSA = particle size average, protein EE = protein encapsulation efﬁciency, % release = total
cumulative percentage of dual dAb detected from in vitro release, % residual= percentage of dual dAb retained inmicroparticles, %mass-balance= sumof released and residual dual dAb.
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sponses. VEGF immunoassays showed that in vivo released dual dAb
was functionally active, (Fig. S3B). Given the ADA responses to dual
dAb in rabbit, further studies were undertaken in primates to reduce
the impact of immunogenicity.
3.5. Ocular PK from dual dAb-loaded microparticles in primates
An ocular and systemic (intravenous) PK assessment of naked dual
dAb in Cynomolgus determined both vitreous and serum (from ocular
and systemically administered), dual dAb half-lives, to be 3–3.5 days
(without ADA), (Table S2, Fig. S4A & S4B). A longer ocular PK study in
Cynomolgus after IVT injection of formulations: 72B, 72E and 72F was
performed to assess ocular tolerance and immunogenicity of the dual
dAb formulations. The aim was to conﬁrm PK data from the rabbit mi-
croparticle study (Fig. S3B), utilising formulations retaining dual dAb
functionality and integrity in vitro for the longest time (Fig. 2B, C). The
study was performed in two phases, (Fig. 3A, Table S3), data
summarising intravitreal dual dAb levels released from the 3 formula-
tions over 6 months are shown in Table 2 and are from one eye in a sin-
gle animal (Phase I), or a mean of OS (left) and OD (right) eyes from the
same animal for each time point (Phase II). 72F maintained the highest
concentrations of dual dAb on day 169 (Table 2), at 4–5 μg/ml. SerumPK
data from the 2 Phase II animals dosedwith 72F are shown in Fig. 3B, to-
gether with modelled vitreous time courses based upon simulated in
vitro and serum release proﬁles for 72F in Cynomolgus in Fig. 3C (Fig.
S5 and Table S3). 72F maintains signiﬁcant dual dAb levels over
6 months in the primate eye (Table 2); ADA analysis (Table S4) con-
ﬁrmed little impact on this experiment.
3.6. Ocular efﬁcacy from dual dAb-loaded microparticles in Cynomolgus
An ocular efﬁcacy, laser CNV experiment was performed in Cyno-
molgus after IVT injection of 72F with the aim to demonstrate protec-
tion in this model [17]. A schematic design is shown in Fig. 4A. The
non-human primate (NHP) laser CNV model typically has an incidence
of 20–60% of laser spots developingGrade IV lesions by 2–3weeks post-
laser [18].
The aim was to determine whether a single administration of dual
dAb would prevent CNV when administered in 72F (Group 2), over 3–
4 or 5–6 months. Additionally, 2 different doses of naked molecule
(Group 3), which matched modelled ‘burst’ and ‘trough’ release levels
of dual dAb, (Fig. 4A), from 72F in the cyno PK study, (Table 2, Fig.
3C), where also analysed for protection in the laser-induced model of
wet AMD. Eylea® (aﬂibercept) at 2 mg/eye (clinical dose) was used as
both negative and positive control, dependent upon administration
timing ahead of laser exposure, (Group 4). Naked aﬂibercept at
human clinical doses was chosen for this control as it is predicted to be-
come the SoC for treatment of wet AMD, [1].
Selection of eyes for each laser event is detailed in Table S5. Individ-
ual animal grade IV laser CNV lesion scores are shown in Table S6; a
summary of the results, including statistical analysis, are shown in
Table 3, where only separate eyes from ADA-free animals areconsidered. Example retinal ﬂuorescence angiograms, (FA), from ani-
mals dosed with empty and dual dAb-loaded microparticles and
aﬂibercept, (positive control), are shown in Fig. 4B.
Serum PK and ADA to dual dAb were monitored throughout, (Fig.
S6), and ocular PK and ADA analysis were taken from animals selected
post-laser for euthanasia, (Table S7, S8). In ADA free animals, intact
serum dual dAb was detectable at 9 months. The Vh/Vk assaymeasures
molecular integrity whereas the VEGF assay shows functional activity,
evenwith partialmolecule breakdown. A comparative analysis between
the two assays suggests that molecular breakdown in vivo was not a
major contributor to differences in dual dAb sera levels from these as-
says over time (Fig. S6C).
IVT injection with aﬂibercept was both a positive control (OS) and a
comparator article (OD) in this study. Injection (OS) at day 141 and laser
at day 148, led to complete inhibition of Grade IV CNV formation (0%),
days 14 and 21 post-injection (Table 3, S6 and Fig. 4B and C). No inhibi-
tion of Grade IV CNV occurred post-laser, days 14 (38.9%) and 21
(31.5%) when laser treatment was 3–4 months post aﬂibercept dose,
(OD), this is consistent bothwith the known half-life of aﬂibercept lead-
ing to clearance and no protection and an expected laser lesion frequen-
cy from historical data of negative control animals (19).
Inhibition of Grade IV CNV by dual dAb-loaded 72Fwas impacted by
ADAdevelopment. ADA responses appeared atweek 9 post-dose in sera
of 5 animals given 72F (Table S8), and continued through induction of
lesions. ADA-positive eyes were removed from data analysis, (Table
S6, Fig. S6) and 72F treated ADA-negative eyes (Table 3) had an inci-
dence of Grade IV laser CNV of 7.4–9.3% (day 92) and 4.4–11.1% (day
148). Of the 5 ADA-negative eyes after day 148 laser, in 4, Grade IV
CNV was completely absent, (0/9). The study was powered to detect a
near complete inhibition of Grade IV CNV lesions, (n = 6). Original
72F-dosed animals, (n=10)were reduced (n=5), by early euthanasia
or ADA presence. As this was only one animal less than anticipated, a
comparative statistical analysis was performed using both the Fisher's
exact test and Poisson regression, (Dunnett's test). Differences between
72F and empty microparticle dosed animals lasered at day 92 were not
statistically signiﬁcant, perhaps because lesion formation in the nega-
tive control group was at the low range of what is normally observed
(Table 3), [20], Differences between 72F and aﬂibercept dosed animals
(OD) at day 92when aﬂibercept levels were exhausted were statistical-
ly signiﬁcant (Table 3, Table S9). At the day 148 laser, both tests sup-
ported a statistical difference, 5–6 months post-dose, between levels
of Grade IV CNV in 72F dosed ADA-negative, compared to emptymicro-
particle dosed animals, (Table 3, Table S9), [14,15,16,20], indicating that
dual dAb release at 6 months was sufﬁcient to ameliorate Grade IV le-
sion development. A graphical comparison of the range of Grade IV le-
sion responses across the groups after the 2nd laser (Table 3, S6) is
shown in Fig. 4C, demonstrating the statistical difference (***P b 0.001,
Fisher's exact test) when only ADA negative animals (circles) are con-
sidered. Further analyses performed on the laser CNV ﬁndings within
treatment groups included grade II and III lesion assessment as these
have increased hypoﬂuorescence and leakage in ﬂuoroscein angiogra-
phy (FA), Fig. 4D [21]. Data conﬁrmed dual dAb levels released at
6 months from 72F resulted in signiﬁcant reductions in CNV lesion
Fig. 2. (A) Release-rate/day for: 72A, 72B, 72C, 72D, 72E and 72F. All data is displayedwithout error bars for clarity of comparison, for release-rate/day, SD across triplicate samples at each
time point for all formulations ranged from±0.2% to±25% ofmean calculated values. Activity and integrity of dual dAb released from 72A-72F in vitro: (B) Percentage functional activity
and intact molecule, for percentage functional activity/intact molecule scoring, SD across replicates, (2–3 samples) at each time point ranged from ±0.7% to ±25% of mean calculated
percentage values (C) Functional activity of dual dAb released from 72B, 72E and 72F at D182 by inhibition of VEGF R2 RBA cf. dAb-Fc, Fc-dAb and aﬂibercept. Samples #1 and #2 were
analysed on the same day on separate plates, (Fig. S2 and Table S1). SD error bars can be seen on some samples but variation is so low in other samples that these are within the
region of the plotted symbol.
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dosed animals. In support of this conclusion, naked dual dAb at the pre-
dicted ‘trough’ 16 μg (1.9%) and ‘burst’ 160 μg (0%) per eye doses, expect-
ed to be released by 72F, were effective at preventing Grade IV CNV
lesions at 14/21 days post-dose/post-laser (Table 3, Fig. 4).
3.7. Adverse events in long term ocular PK and efﬁcacy studies in
Cynomolgus
Adverse and unexpected events occurred in both ocular microparti-
cle studies in Cynomolgus: particle migration from vitreous to anteriorchamber, (Fig. 5A), delayed polymer breakdown, (Fig. 5B) and ocular in-
ﬂammation, (Fig. 5C).
Microparticles ﬁrst appeared in the anterior chamber at day 3 after
IVT injection, moving through the vitreous andmigrating into the ante-
rior chamber, (Fig. 5A). The frequency and volume of migration in-
creased with time, peaking at day 60 and occurring for both empty
and dual dAb-loaded microparticles, (Tables S10A, S10B). In the PK
study, migration occurred in 11/18 eyes (61%) and for the efﬁcacy
study in 13/32 eyes (41%): an average of 48%. Fig. 5A shows an example
where microparticles are seen as a white crescent, (OS, anterior cham-
ber), day 16, the total amount increasing at day 64. The similarly
Fig. 3. PK from single IVT injection of dual dAb-loadedmicroparticles into Cynomolgus eye. OD= right eye, OS= left eye, (A) schematic PK experimental design, Gp=group, Ph=phase,
Aq tap = aqueous humour sample, (B) serum concentration proﬁles from two 72F–dosed animals, (C) actual (VEGF MSD) and modelled, (in vitro released, red line, Fig. 1D; serum-
released, blue line, Fig. S4D), vitreous dual dAb concentrations (Table 2, Table S3), purple (◊) = data points (Table 2).
Table 2
Summary of intravitreal dual dAb levels in Cynomolgus after dosing with 72B, 72E and 72F.
Formulation Dose/eye
microparticle in mg
(dual dAb in μg)
Intravitreal
dual dAb μg/ml
phase I day 57 (OS)
Intravitreal
dual dAb μg/ml
phase I day 71 (OD)
Mean intravitreal
dual dAb μg/ml
phase I day 113
Mean intravitreal
dual dAb μg/ml
phase II day 169
72B 7.5 mg (1136 μg) 13.30 17.70 7.95 1.53
72E 6.0 mg (1116 μg) 13.40 11.20 1.69 0.77
72F Phase I†: 6.0 mg
(1304 μg)
2.85†,⁎ 3.72†,⁎
Phase II§: 3.0 mg (652 μg) 5.09§ 4.03§
† Data from animal I08251, dosed in phase I, at twice the dose of animals dosed with 72F in phase II§.
⁎ intravitreal drug levels should be interpretedwith caution, animal I08251 had developed a serumADA response to dual dAb, (d29) and vitreal ADAwas present at d71, (Table S4). For
72B, data is from animal I08245 at d57/71, I08246 (d113) and I08247 (d169); for 72E, data is from animal I08248 at d57/71, I08249 (d113) and I08250 (d169) and for 72F, data is from
animal I08251 at d57/71, I08253 (d113) and I08252 (d169), Table S3.
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Fig. 4. Efﬁcacy from single IVT injection of dual dAb-loaded microparticles into Cynomolgus eye. (A) Schematic efﬁcacy experimental design, MP = microparticles. (B) Representative
ﬂuorescein angiograms (FA), 14 days after 2nd laser (Table 3) from empty (Group 1) and dual dAb-loaded (Group 2) microparticle dosed animals and positive control, aﬂibercept,
(Group 4), dosed 1 week before laser. x/9 = grade IV lesion score; (C) Box plot, average percentage grade IV lesions after 2nd laser for Groups 1, 2 and 4 and laser for Group 3 (naked
dual dAb 2 doses): data across groups, columns = means, vertical lines = full response ranges, circles = means (ADA negative animals), ***P b 0.001, (D) Box plot, individual lesion
grades, after 2nd laser for Groups 1, 2, 4 and laser for Group 3, (naked dual dAb: 2 doses). Boxes show 25th to 75th percentiles, (box absence means both percentiles equal a lesion
grade of 1), vertical lines = full response ranges, circles = median.
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Table 3
Summary of protection against grade IV laser CNV lesions in Cynomolgus (ADA free) by naked and slow-released dual dAb from a single IVT dose.
Group
(time of laser)
Number of eyes lasered
(separate ADA free animals)
Grade IV lesions/burn
day 14 post laser (%)
Grade IV lesions/burn
day 21 post laser (%)
Statistical analysis by
Fischer's exact test P-value,
data: (i) day 14, (ii) day 21
Control or
test group
Comments
Group 1
empty MPs
(day 92)
6 9/54 (16.7%) 10/54 (18.5%) See Group 2 (day 92 laser) Negative control Low lesion number
for a negative control
Group 2
72F
(day 92)
6 4/54 (7.4%) 5/54 (9.3%) (i) d14 Group 1 v Group 2,
P = 0.236
(ii) d21 Group 1 v Group 2,
P = 0.265
Test 3 animals have been
excluded as ADA + ve
Group 4
aﬂibercept (OD)
(day 92)
6 21/54 (38.9%) 17/54 (31.5%) (i) d14 Group 2 v Group 4,
P b 0.001
(ii) d21 Group 2 v Group 4,
P = 0.008
Negative control Expected lesion number
for a negative control
Group 1
empty MPs
(day 148)
6 24/54 (44.4%) 24/54 (44.4%) See Group 2 (day 148 laser) Negative control Expected lesion number
for a negative control
Group 2
72F
(day 148)
5 5/45 (11.1%) 2/45 (4.4%) (i) d14 Group 1 v Group 2,
P b 0.001
(ii) d21 Group 1 v Group 2,
P b 0.001
Effective
Test 1 animal has been
excluded as ADA + ve
Group 4
aﬂibercept (OS)
(day 148)
6 0/54 (0%) 0/54 (0%) (i) d14 Group 1 v Group 4,
P b 0.001
(ii) d21 Group 1 v Group 4,
P b 0.001
Effective
Positive control Aﬂibercept dose at
day 141 (OS)
Group 3 ⁎
16 μg
dual dAb
(day 1)
6 1/54 (1.85%) 1/54 (1.85%) Effective Test + last 4/6 eyes dosed
had inﬂammation due
to LPS contamination
Group 3 $
160 μg
dual dAb (day 30)
6 0/54 (0%) 0/54 (0%) Effective Test
Eyeswere dosedwith, Group 1: emptymicroparticles (MPs), Group 2: dual dAb-loadedmicroparticles: 72F; Group 3, 2 different doses of naked dual dAb and simultaneously lasered: ⁎day
1, right eye (OD) 16 μg and $day 30 left eye (OS) 160 μg; Group 4: aﬂibercept (2 mg), day 1 right eye (OD), day 141 left eye, (OS), Fig. 4A.
8 P. Adamson et al. / Journal of Controlled Release 244 (2016) 1–13dosed OD from the same animal shows no particle migration. Isolation
of 72Fmicroparticles from aqueous humour at 6months and size deter-
mination by lightmicroscopywere similar to those originally dosed into
vitreous. The exact mechanism of movement remains unresolved.
Of concern were observations that ocular 72F polymer breakdown
rate was slower than molecule release rate. Microparticle degradation
ratewas not quantiﬁed; small numbers of Cynomolgus eyeswere imaged
6–12 months post dose, (Fig. 5B) and show that polymer material in the
vitreous reduces from 6 to 12 months but there is not full degradation.
By 12 months, in vitro release of dual dAb from 72F was 84% complete
(Table 1). In similar rabbit studies, 72F microparticle pellets were recov-
ered from vitreous after six months and were partially degraded.
Acute transient inﬂammation occurred in Cynomolgus after IVT ad-
ministration of all microparticle formulations in both PK and efﬁcacy
studies (Table S11). Ocular histopathology was performed after eutha-
nasia for selected animals from the efﬁcacy study, to review inﬂamma-
tory and morphological effects (Table S12). Fig. 5C shows examples of
such effects: microparticles in ventral ﬁltration angle and organizing
connective tissue (I00072) and anterior segment inﬂammation
(I00085). Microparticles and macrophage/multinucleate giant cell in-
ﬂammation correlated with ophthalmic examination ﬁndings of vitre-
ous haze and/or vitreous cells. Perivascular sheathing was seen in
some animals in both studies and was linked to ocular ADA and blood
retinal barrier (BRB) breakdown enabling entry of systemic ADA in to
the vitreous (Table S4, S8). Veterinary intervention was required inFig. 5.Adverse events in Cynomolgus eye after IVT injection ofmicroparticles. (A)Movement of
2: 72F) from efﬁcacy study, at two different times. (B)Microparticle presence in Cynomolgus ey
(IR) mode on Heidelberg Spectralis instrument with ultra-wide angled lens, from 6 to 12 m
temporal panels can be aligned using laser burn remnant. (C) Analysis by histopathology. Im
study. Microparticles and multinucleated giant cells are highlighted in ventral ﬁltration angle
tissue in vitreous. Anterior segment inﬂammation is shown in animal I00085 (Group 2: 72F) asomemicroparticle-dosed animals to control sporadic ocular inﬂamma-
tion. Two animals dosed with dual dAb-loaded microparticles showed
ocular inﬂammation, driven by severe persistent ADA leading to early
euthanasia; although some animals dosed with 72F were monitored
for 9–12 months without major issues.
4. Discussion
Cynomolgus studies demonstrated ocular PK and efﬁcacy over
6 months following a single IVT administration of 72F. The effect on
Grade IV CNV lesions is important because these closely resemble active
classical CNV lesions seen in human AMD [17]. Three further hurdles
would need to be addressed to translate this and potentially other par-
ticulate IVT injectable controlled release systems delivering biologic
VEGF inhibitors in to a drug product for clinical use:-
(i) particle migration from vitreous to anterior chamber,
(ii) delayed polymer breakdown compared to payload release,
(iii) ocular inﬂammation (both acute initial and later stage anti-mol-
ecule immunogenicity).
Although all three issues were highlighted for both empty and dual
dAb-loaded microparticles in the Cynomologus studies described in
this work, there are further complications of later stage inﬂammatory
responses that could additionally be contributed to by ADA/microparticles from vitreous to anterior chamber. Images fromboth eyes of I00085 (Group
ewith time. Images taken from both eyes of I00075 (emptymicroparticles) using infra-red
onths post-injection. Microparticles, reﬂecting light are in white area at the image base,
ages taken from eyes of animals euthanized at day 170, after second laser, from efﬁcacy
of animal I00072 (OS, Group1: empty microparticle-dosed) with organizing connective
t both low and high magniﬁcation. Scale bar, 200 μm.
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loaded microparticles.
One explanation for particlemigration ismovementmediated by ac-
commodation mechanisms in young primates, driven by ciliary muscle
changes upon disaccommodation, leading to ﬂuid ﬂow and microparti-
cle migrations from vitreous to anterior chamber [22,23,24]. No migra-
tion was observed in multiple IVT-injected microparticle rabbit studies,
but rabbits have different accommodation mechanisms compared to
NHPs and humans [25]. Researchers developing particulate systems
for IVT injection have not previously reported this ﬁnding, however, tri-
amcinolone in the rhesus monkey [22] and other particles have been
seen to move from vitreous to anterior chamber [26], Mary Ann Croft,
personal communication]. This was described with Indian Ink particles
in the early 20th century [27] and some clinical cases present a
pseudohypopyon after IVT injection, consisting of triamcinolone crys-
tals in the anterior chamber [28]. Although many elderly patients with
wet AMD may lose full accommodative function, this can deteriorate
both in aged NHPs and at N50 years inman [29,30]. Further work in pri-
mates would need to mitigate these concerns prior to the clinic. It may
be difﬁcult for long termparticulate delivery systems to progress via IVT
injection in man [31]. Replacing particulates with solidifying erodible
injectable gels may circumvent some of these issues [32,33].
PolyActive polymers as implants or delivery systems have been
studied extensively in pre-clinicalmodels, also in the clinic in the subcu-
taneous setting [12,13,4,34–37], but degradation rate and compatibility
within the eye have not been previously studied. Historical work sug-
gested a potential 9month breakdown time in vivo, a 6–9month break-
down time would most likely be acceptable for the release kinetics
demonstrated in these studies. Studies in the rabbit eye did not predict
the largemass ofmicroparticles visualised 10–12months post IVT injec-
tion in Cynomologus, (Fig. 5B). In vitro release studies did suggest mi-
croparticles could remain intact for 12 months but degradation was
expected to be accelerated in vivo [12,13,34–37]. Also the rabbit studies
also did not demonstrate the particle migration, the combination of the
two phenomenon in Cynomolgous and likely man would limit re-dos-
ing of formulations that showed both migration and slow-degradation.
Acute initial ocular inﬂammation may have been avoided using for-
mulations prepared using good manufacturing practice (GMP) with
highest purity raw materials, but in current studies, microparticles
were prepared aseptically and contaminants and leachables such as en-
dotoxin and dichloromethane (DCM) were below acceptable limits.
Note that in the rabbit studies described in this work, (Fig. S3), and
other rabbit studies with PolyActive microparticles from these batches,
initial ocular inﬂammation was not as acute as in the Cynomolgus. Sur-
face hydrophobicity can contribute to nanoparticle biocompatability is-
sues in lung [38]. PolyActive microparticles are amphiphilic consisting
of hydrophilic (PEG) and hydrophobic (PBT) components, with PEG
being close to the surface. It seems unlikely hydrophobicity is a major
contributor to rapid transient inﬂammation which was similar across
all PolyActive formulations dosed in the PK study, although 72B and
72E are less hydrophobic than 72F. An increase in microparticle hydro-
phobicity with time as PEG dissociates, could contribute to later inﬂam-
mation in the two Cynomolgus studies, but anti-molecule ADA links to
later and more severe inﬂammatory responses and could be solely
responsible.
Ocular inﬂammatory damage from ADA responses to dual dAb may
primarily be a reaction to humanised protein in Cynomolgus. The mol-
ecule is clearly highly immunogenic in rabbit. The speciﬁcity of the
ADA was further characterised in both rabbit and Cynomolgus (ten
samples), and themajority of the response was to the complementarity
determining regions, (CDRs) binding to VEGF, within the intact dual
dAb molecule and largely to the CDRs within the Vh dAbs. In some
cases in Cynomolgus, impact was severe andwould be concerning if di-
rectly translated toman.However, other biologics that have high immu-
nogenicity in pre-clinical species have been licensed and are marketed
drugs in man: one example is the anti Tumour Necrosis Factor (TNF)monoclonal antibody adalimumab (Humira), [39], although early
ranibizumab (Lucentis), formulations were also inﬂammatory in pre-
clinical species [40]. Dual dAb has been screened for pre-existing immu-
nogenicity using sera from a small panel of human donors and ADA
responses were not detected. Development of post-dose ADAs would
need to be explored inman for amultiple administration regime. Ocular
reaction tomicroparticles and anymigrationwould need careful control
in the human setting.
Key factors enabling the successes described in this study are the co-
evolution of a delivery system and potent molecule, highly stable over
time, compatible with aqueous, hydrogel formulation, with effective
function even after reductions inmolecular integrity. Dual dAb degrada-
tion after release in vitro was partial up to 365 days and explicable by
combinations ofmetal ion induced immunoglobulin hinge and protease
linker cleavage. Similar degradation paths could be seen in accelerated
breakdown studies of naked molecule so there does not appear to be
signiﬁcant particle-induced degradation of the molecule, in contrast to
the behaviour of poly lactic-co-glycolic acid, (PLGA) microparticles
[41]. PolyActive hydrogel formulation 72F retained dual dAb functional
activity over 6–12months both in vitro and in vivo and controlled a size-
dependent release rate over time. Other key features are the ability to
concentrate the molecule to N200 mg/ml as a solution, a high percent-
age protein loading tomicroparticles (≥22%w/w) and a simple injection
enabling maximum theoretical particle dose (up to 7.5 mg or 15%) in a
50 μl volume via a 30 g needle and 0.5 ml syringe.
5. Conclusions
A single 72F injection is efﬁcacious in the cynomolgus laser CNV
model at 6 months, but translating efﬁcacy to man requires mathemat-
ical modelling. Multiple lines of evidence, including in vitro potency,
dual dAb enhanced stoichiometry [10], comparable size and ocular PK
[19] and similar vitreal concentrations of naked dual dAb compared to
aﬂibercept at the time of protection in ocular efﬁcacy models (ca. 8 μg/
ml, Fig. 6A, [42]) demonstrate that dual dAb is at least equipotent to
aﬂibercept in vivo.Maintenance of dual dAb vitreous levels similar or
greater than aﬂibercept therefore should predict efﬁcacy in wet AMD
patients.
An initial step converting Cynomolgus ocular PK to human is in un-
derstanding how in vivo release of dual dAb from72F differs from that in
vitro. Simulations of Cynomologus vitreous and serumPKwere obtained
using a two compartmental model of vitreous and serum, and the in
vitro release data, (Fig. 6B: red traces) andwere found to be signiﬁcantly
different to observed PK data (Fig. 6B: blue and purple traces). These
simulations show that in vivo release is faster than in vitro over the
ﬁrst few months and that microparticles become exhausted of dual
dAb faster in vivo, leading to slower release beyond 6 to 7 months.
This ﬁnding is not unexpected asmany polymers do not show a directly
comparable release rate for proteins both in vitro and in vivo, although
PolyActive shows quite a close relationship [12,13]. A faster ‘burst’ re-
lease in vivo compared to in vitro could be related to the more dilute
concentration in vivo, or to the initial acute inﬂammatory response
seen in Cynomolgus. Themost likelyﬁrst step is the initial release of sur-
face bound PEG from themicroparticles and thismay have been faster in
vivo than in vitro and perhaps led to increased protein release.
Human vitreal dual dAb PK was simulated (Fig. 6C, blue line) by
adjusting the vitreal volume and half-life in the Cynomolgus two com-
partmental model based upon the larger human eye. Dual dAb vitreal
release was simulated using an estimated human dose, which had al-
ready been achieved in the Cynomolgus studies (7.5 mgmicroparticles,
22% loading of 1.7mgdual dAb) in 50 μl injection volume and the in vivo
release rate previously ﬁt to the Cynomolgus efﬁcacy PK data for 72F.
For comparison, SoC (ranibizumab and aﬂibercept) PK was simulated,
(Fig. 6C, green and red lines, respectively), using known or estimated
vitreous clearances; both fall to similar trough levels (ca. 7 μg/ml) in
line with their market labels at 1 and 2 months respectively. Initial
Fig. 6. Modelling long term 72F/dual dAb ocular PK in Cynomolgus and human. (A) Schematic of lowest aﬂibercept dose preventing Cynomolgus grade IV laser CNV lesions [42],
superimposed with mean Cynomolgus dual dAb vitreous levels, after four and six months release, extrapolated from 72F in the PK study, (Fig. 3A, B, C and Table 2), and low dose of
naked molecule from the efﬁcacy study, (Fig. 3A), (B) simulation of dual dAb release rate from 72F using, in vitro release rate and serum PK in Cynomolgus from both PK (Fig. 3B,
Fig. S5D, Table S3) and efﬁcacy studies (Fig. S6, Table S8). Open purple diamonds are data points. (C) Predicted human vitreous PK from a single dose of dual dAb-loaded
microparticles (72F), ranibizumab and aﬂibercept.
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aﬂibercept, simulated human vitreous levels of dual dAb still exceed
SoC at 6months indicating real potential for an effective 6-monthly dos-
ing regime.
If the other challenges highlighted in the discussion can be resolved,
single administration of an anti-VEGF biologic formulation could be pos-
sible to increase patient/provider compliance and relieve patient bur-
den in wet AMD.
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